The Prognostic Value of Serum Inflammatory Markers in Nasopharyngeal Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Multicenter Study
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.72032 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 12.06.2026. Verfasst von Yang Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Wu-Ming Hospital of Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immune Checkpoint Inhibitors, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Independent Project of Key Laboratory of Early Prevention & Treatment for Regional High-Incidence-Tumor, Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation, the Key Research and Development Program Project of Guangxi Zhuang Autonomous Region.
Abstract (Originalsprache)
Background
Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment of nasopharyngeal carcinoma (NPC), reliable predictive biomarkers need to be further explored. This study aimed to investigate the predictive ability of inflammatory markers for poor prognosis in NPC patients treated with ICIs.
Methods
In this multicenter retrospective study, a total of NPC patients treated with at least two cycles of ICIs from May 2019 to December 2022 at three independent medical centers in China were included. In this study, we collected the multiple hematological parameters from patients prior to treatment to calculate serum inflammatory markers, and we performed the multivariate COX analysis to identify independent prognostic factors for constructing columnar plots. Then the ROC survival curves, calibration curves, and clinical curve analysis were used to assess the predictive performance of the model.
Results
A total of 170 patients were included in the training group with a median follow‐up of 26 months. Univariate and multivariate Cox regression analyses showed that Hb, Prognostic Nutritional Index (PNI), and the number of metastases were independent prognostic factors for overall survival (OS). A nomogram was constructed based on these three factors to predict the prognosis of NPC patients after ICI treatment. The nomogram achieved a C‐index of 0.733 in the training cohort and 0.743 in the validation cohort, indicating good discriminative ability. Time‐dependent ROC curves demonstrated favorable predictive accuracy, with area under the curve (AUC) values for 1‐, 2‐, and 3‐year OS of 0.701, 0.756, and 0.760 in the training set, and 0.773, 0.784, and 0.777 in the validation set. The model was further validated using calibration plots and decision curve analysis (DCA), and patients were categorized into high‐ and low‐risk groups, with the validation cohort also showing consistent survival differentiation.
Conclusion
The combination of serum inflammatory markers and clinicopathological factors may serve as a practical prognostic tool to predict NPC patients who may benefit from ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Wu-Ming Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
- Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education/Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency…
- Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China.
ORCID-Profile: Kaihua Chen, Wenqi Liu, Xiaodong Zhu
Förderung
- the Independent Project of Key Laboratory of Early Prevention & Treatment for Regional High-Incidence-Tumor
- Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation
- the Key Research and Development Program Project of Guangxi Zhuang Autonomous Region
Zitieren
APA
Xu, Y., Xie, J., Zhang, D., Zhu, L., Chen, X., Zhang, Q., Lv, H., Chen, K., Li, L., Qu, S., Chen, X., Liu, W., & Zhu, X. (2026). The Prognostic Value of Serum Inflammatory Markers in Nasopharyngeal Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Multicenter Study. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.72032
Vancouver
Xu Y, Xie J, Zhang D, Zhu L, Chen X, Zhang Q, et al. The Prognostic Value of Serum Inflammatory Markers in Nasopharyngeal Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Multicenter Study. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.72032
BibTeX
@article{Xu2026,
author = {Xu, Yang and Xie, Jingyi and Zhang, Danmeng and Zhu, Liru and Chen, Xiaojun and Zhang, Qingqing and Lv, Haoyu and Chen, Kaihua and Li, Ling and Qu, Song and Chen, Xishan and Liu, Wenqi and Zhu, Xiaodong},
title = {The Prognostic Value of Serum Inflammatory Markers in Nasopharyngeal Carcinoma Patients Treated With Immune Checkpoint Inhibitors: A Multicenter Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.72032}
}
EUVIMED